Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...

Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return ...

CVS Caremark, Express Scripts and Optum Rx — the three largest pharmacy benefit managers in the U.S. — each excluded more ...

As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in ...

Alvotech (NASDAQ: ALVO, or the "Company"), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of ...

The company’s ability to capitalize on biosimilar opportunities, particularly with drugs like HUMIRA, is viewed as a potential catalyst for future growth. However, Cigna operates in a highly ...

Alvotech acquires Xbrane's R&D operations and biosimilar candidate XB003 for ~$27M, expanding into Sweden's life sciences sector. Xbrane retains key preclinical assets, strengthens finances ...

A RECENT cohort study comparing the effectiveness of adalimumab biosimilars Amjevita and Imraldi with the originator Humira for psoriasis found no significant differences between the treatments. The ...